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Available online 14 January 2016Objectives: Adjunctive host-directed therapy is emerging as a new potential approach to improve the outcome of
conventional antimicrobial treatment for tuberculosis (TB).We tested the ability of a phosphodiesterase-4 inhib-
itor (PDE4i) CC-11050, co-administered with the ﬁrst-line anti-TB drug isoniazid (INH), to accelerate bacillary
killing and reduce chronic inﬂammation in the lungs of rabbits with experimentalMycobacterium tuberculosis
(Mtb) infection.
Methods: A rabbit model of pulmonary TB that recapitulates the pathologic manifestations seen in humans was
used. Rabbits were infected with virulent Mtb by aerosol exposure and treated for eight weeks with INH with
or without CC-11050, starting at four weeks post infection. The effect of CC-11050 treatment on disease severity,
pathology, bacillary load, T cell proliferation and global lung transcriptome proﬁles were analyzed.
Results: Signiﬁcant improvement in bacillary clearance and reduced lung pathology and ﬁbrosis were noted in
the rabbits treated for eight weeks with INH + CC-11050, compared to those treated with INH or CC-11050
only. In addition, expression of host genes associated with tissue remodeling, tumor necrosis factor alpha
(TNF-α) regulation, macrophage activation and lung inﬂammation networks was dampened in CC-11050-
treated, compared to the untreated rabbits.
Conclusions: Adjunctive CC-11050 therapy signiﬁcantly improves the response of rabbits with experimental pul-
monary TB to INH treatment.We propose that CC-11050may be a promising candidate for host directed therapy
of patients with pulmonary TB, reducing the duration and improving clinical outcome of antibiotic treatment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Inﬂammation1. Introduction
Tuberculosis (TB), caused byMycobacterium tuberculosis (Mtb) is a
common infectious disease among humans, accounting for 9 million
new cases and 1.5 million deaths in 2013 (http://www.who.int/tb/
publications/factsheet_global.pdf?ua=1). The current anti-TB drug reg-
imen used for directly observed therapy, short course (DOTS) is ineffec-
tive at completely eliminating the infecting Mtb and disease associated
lung pathology (Mitchison, 2000; Sirgel et al., 2000). Since most of the
antibiotics currently in use for TB treatment under DOTS primarily
target actively growing Mtb, non- or slow replicating and dormant ba-
cilli, present in the granulomas of active TB cases, are not efﬁcientlyal Immunity and Pathogenesis,
A.
n).
eattle, WA, USA.
. This is an open access article underkilled (Mitchison, 2000; Zhang et al., 2012). Such dormant bacillary
population can resume growth and cause symptomatic, active disease
in the infected host in response to conditions that suppress immunity
(Cardona, 2010; Ehlers, 2009). Moreover, after successful completion
of DOTS therapy, lung function and quality of life of TB patients can be
signiﬁcantly compromised by the ﬁbrotic scars and irreversible tissue
damage, rendering them more susceptible to recurrent TB disease
and other pulmonary infections (den Boon et al., 2008; Verver et al.,
2005). Therefore, alternate approaches for better bacterial elimination
and treatment outcome are urgently needed to control the TB epidemic
and improve the quality of life of TB patients after treatment (Zumla
et al., 2014).
Progression of initial pulmonary Mtb infection to chronic active TB
versus establishment of latent Mtb infection (LTBI) involves a shift
in the regulation of inﬂammatory responses of host immune cells
(Dorhoi & Kaufmann, 2014; Behar et al., 2014). During progressive
pulmonary TB, the onset of early and exacerbated inﬂammation, associ-
ated with tissue necrosis and cavity formation impairs host resistancethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Kaufmann & Dorhoi, 2013; Sugawara, 2009). Disease pathology during
Mtb infection is driven by reactive oxygen and nitrogen species as well
as cytokines, chemokines and other inﬂammatory mediators such as
TNF-α, interferon gamma-induced protein 10 (IP-10) and C-reactive
protein (CRP) produced by activated macrophages, neutrophils and
other immune cells (Kaufmann & Dorhoi, 2013; Schlesinger, 1996).
Themycobacterial population thriving in anelevatedhost inﬂammatory
environment adapts to a dormant phenotype with slow or no replica-
tion that is refractory to antibiotic killing (Chao & Rubin, 2010). Thus,
adjunctive host targeted immune therapies that improve disease pa-
thology by modulating the inﬂammatory response to Mtb infection
and that shorten the duration of standard antibiotic treatment by in-
creasing macrophage anti-microbial activity, is an important emerging
concept in treatment of TB (Wallis & Hafner, 2015; Hawn et al., 2015).
Phosphodiesterases (PDE) are enzymes that hydrolyze cyclic nucleo-
tides, such as cyclic adenosine and guanosine monophosphates (cAMP
and cGMP) (Francis et al., 2011; Conti et al., 2003). In higher mammals
at least 11 different PDEs (PDE1–PDE11) have been reported; many are
implicated in modulating host cell functions, including cytokine
and chemokine produced in response to various diseases (Keravis &
Lugnier, 2012; Bender & Beavo, 2006). PDE4 is a cAMP-speciﬁc hydro-
lase present predominantly in host leukocytes, including macrophages,
neutrophils and lymphocytes (Spina, 2003; Houslay et al., 1998). Since
accumulation of cAMP, through blocking its hydrolysis, negatively regu-
lates inﬂammation, several PDE4is have been tested and found to be
useful for treating human inﬂammatory diseases including asthma
and psoriasis (Spina, 2003; Azam & Tripuraneni, 2014; Maurice et al.,
2014). Over the past several years, we have investigated the therapeutic
effects of the immune modulatory drugs (IMiDs®), PDE4i, and other
small molecules as adjunctive therapies with anti-TB antibiotics in dif-
ferent animal models (Moreira et al., 1997; Tsenova et al., 2002; Koo
et al., 2011; Subbian et al., 2011a; Subbian et al., 2011b). Our central hy-
pothesis is that reducing but not fully blocking TNF-α production by
host cells would alleviate inﬂammatory responses and improve the out-
come of antibiotic treatment duringMtb infection. Recently, we showed
that treatmentwith the PDE4i CC-3052, together with INH, signiﬁcantly
reduced Mtb growth and disease pathology in murine and rabbit
models of pulmonary TB (Koo et al., 2011; Subbian et al., 2011a;
Subbian et al., 2011b). In the present study, we report the “proof-of-
concept” for the activity of another PDE4i (CC-11050) with improved
therapeutic properties. Moreover, CC-11050 has an investigational
new drug (IND) application and has been in clinical trials for other indi-
cations. We chose INH, since this drug predominantly kills actively rep-
licating bacteria and ineffective in killing against dormant bacilli. In
addition, INH monotherapy has been used as a prophylactic treatment
against reactivation of latent Mtb infection in humans. Our results
show that CC-11050 dampens infection-induced inﬂammation and
improves bacterial clearance as well as clinical outcome in INH treated
rabbitswith pulmonary TB. The presentwork conﬁrmed that PDE4 inhi-
bition with CC-11050 gives similar effects as CC-3052 and other PDE4is.
Results from this studywill serve as a proof of concept to guide a human
clinical trial that will be conducted soon (JBZ personal communication).
2. Materials and Methods
2.1. Bacterial Culture and Chemicals
M. tuberculosis HN878 (a strain of W-Beijing lineage) was grown to
mid-log phase (OD600=0.5–0.7) inMiddlebrook 7H9media containing
0.5% glycerol, 0.25% Tween 80 and 10% oleic acid dextrose catalase
(OADC) supplement (BD Biosciences, MD) and aliquots were stored
at −80 °C. The bacterial inoculum for rabbit aerosol infection was
prepared as described previously (Subbian et al., 2011c). Ketamine,
acepromazine and euthasol used to sedate and euthanize rabbits were
purchased from Henry Schein Animal Health, OH. CC-11050 wassupplied by Celgene Corporation, NJ. All other chemicals were pur-
chased from Sigma-Aldrich (Sigma-Aldrich, MO), unless mentioned
otherwise.
2.2. Animal Welfare and Ethical Statement
Speciﬁc pathogen free, femaleNewZealandwhite rabbits (Millbrook
Farms, MA) of 2.3 to 2.6 kg body weight were used in this study. Each
rabbit was housed individually without any restriction on food and
water consumption (ad libitum) and was handled humanely according
to the United States Department of Agriculture (USDA) policies. All the
procedures withMtb-infected rabbits, including infection, gavage, post-
infection and treatment monitoring were performed in bio safety level-
3 facilities according to the protocols approved by the Institutional
Animal Care and Use Committee (IACUC) of the Rutgers University
and were in compliance with institutional, national and international
guidelines governing the use of experimental animals.
2.3. Pharmacokinetics of CC-11050
2.3.1. Structure of CC-11050
CC-11050 (N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-
(methylsulfonyl) ethyl]-2,3-dihydro-3-oxo-1H-isoindol-4-yl]-(9Cl)
cyclopropanecarboxamide) is a PDE4i with anti-inﬂammatory activi-
ties. CC-11050 has an empirical formula of C24H28N2O6S with one chi-
ral center in its structure (Supplementary Fig. 1A).
2.3.2. Sample Collection
Uninfected rabbits were divided into two experimental groups
(n = 3 per group) and treated by oral gavage with either 25 mg per
kg or 50 mg per kg of CC-11050. Venous blood was collected in
vacutainer tubes (BD & Co, NJ) at time 0 (pre-treatment), 15 min,
30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after a single gavage administration
of CC-11050. In another experiment, groups of rabbits (n = 3 per
group) were treated by oral gavage with CC-11050 at 25 or 50 mg per
kg per day for four days and blood was collected as before. Plasma
was collected after centrifuging the blood samples at 1100 ×g for
10 min. To determine whether INH and CC-11050 interact with each
other in the Mtb-infected rabbits, blood samples were collected after
2 weeks of treatment and plasma was collected as mentioned above
for liquid chromatography–mass spectrometry (LC–MS) analysis.
2.3.3. Bioanalytical Method for CC-11050
The standard curve (1 to 4000 ng per ml) and quality control sam-
ples (3 to 3200 ng per ml) were prepared by diluting 1 mg per ml
stock CC-11050 solution in rabbit plasma diluted 1:1 with Sorenson's
citrate buffer (25 mM; pH 1.5). The internal working standard solution
(25 ng per ml) was prepared by diluting 1 mg per ml internal standard
stock solution of 13CD3–CC-11050. Brieﬂy, 100 μl of theworking internal
standard solutionwas added to 25 μl of each standard, quality control or
test samples, and mixed well. After centrifugation at 4000 rpm for
10 min, 75 μl of the supernatant was transferred to a clean 96-well
plate for analysis. Samples were analyzed by LC–MS using a Sciex
API 4000 Triple Quadrupole Mass Spectrometer (Sciex, Division of
MDS Inc., Canada) coupled to a Shimadzu HPLC System (Shimadzu Sci-
entiﬁc Instruments, MD) with a Phenomenex Gemini column (5 μm,
2.0 × 50 mm) (Phenomenex, CA). Samples were analyzed using the
following chromatographic conditions: mobile phase A consisted of
0.1% formic acid in water and mobile phase B consisted of 0.1% formic
acid in acetonitrile. The gradient conditions were: 0 min for 10% B,
0.0–2.0 min from 10% B to 75% B, 2.1–3.0 min for 95% B, and 3.05–
4.0 min for 10% B. A positive ion mode with turbo spray, an ion source
temperature of 450 °C, and a dwell time of 100 ms were utilized for
mass spectrometric detection. Quantiﬁcation of analyteswas performed
using multiple reactions monitoring (MRM) at the following transi-
tions: m/z 473.1 tom/z 178.1 and m/z 477.1 to m/z 182.1 for CC-11050
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peak area ratios of analyte to its internal standard versus analyte con-
centrationwere derivedwith 1/x2 weighting. Pharmacokinetic parame-
ters were calculated using Watson LIMS™ (version 7.4, Thermo Fisher,
PA). Themaximumplasma concentration (Cmax) and the corresponding
time (Tmax) were determined from actual data. The area under the plas-
ma concentration-time curve from time 0 to the last measurable time
point (AUClast) was determined using the linear and linear-log trapezoi-
dal rule of non-compartmental model. Nominal times were used for
pharmacokinetic parameter calculations. All statistics were calculated
by Watson LIMS™. Plasma concentrations below the limit of quantita-
tion (BLOQ) were treated as zero for calculation.
2.4. Pulmonary Mtb Infection of Rabbits
Seventy rabbits (n = 71) were used for aerosol infection with Mtb
HN878 in a “snout-only” exposure system (CH Technologies Inc., NJ)
as reported earlier (Tsenova et al., 2006). After oneweek of acclimatiza-
tion, rabbits were sedated and exposed to Mtb-containing aerosols
through individual, “snout-only” apparatus. The bacterial inoculum
was standardized to deliver approximately 3.3 log10 bacterial colony
forming units (CFU). To determine the actual number of CFU implanted,
a group of aerosol-exposed rabbits (n = 10) was euthanized after 3 h
(T = 0) and their lung homogenates were plated on Middlebrook
7H11 agar plates (Difco Laboratories Inc., Detroit, MI). Bacterial CFU
were enumerated from these plates after 4–6 weeks of incubation
at 37 °C. Similarly, CFU were calculated from six animals (n = 6) at
4 weeks post-infection (i.e., at the onset of treatment). Starting at
4 weeks post-infection, group of Mtb-infected rabbits was treated by
oral gavage with CC-11050 (50 mg per kg) or INH (50 mg per kg) or a
mixture of INH + CC-11050 ﬁve days a week for 8 weeks (i.e., until
12 weeks post-infection); a group of Mtb-infected rabbits (n = 7) was
left untreated as control. The treatment compounds were dissolved in
water before oral gavage using a ﬂexible rubber catheter with a lubri-
cant. At 8 and 12 weeks post-infection, Mtb-infected rabbits from all
four groups (n = 6–8 per group per time point) were euthanized and
the lung, liver and spleen were harvested aseptically and processed
immediately to prepare homogenates in sterile saline for CFU assay.
Representative portions of these organs were also stored in formalin
for histopathologic analysis or frozen immediately for total RNA isola-
tion. To monitor disease severity, weight of total body, lung, liver and
spleen was measured and number of sub-pleural lung granulomas
was counted for all the infected rabbits at each experimental time point.
2.5. Mycobacterial Drug Susceptibility Test
Bacterial resistance to INH was tested by plating serial dilutions of
lung homogenates on 7H10 agar media containing 0.2 or 1 μg per ml
of INH. In addition, susceptibility of Mtb strains to INH (0.0125 μg per
ml or 0.2 μg per ml) with or without CC-11050 (5, 50 and 250 mM)
were tested in vitro using liquid cultures. Brieﬂy, about 6 log10 CFU
per ml of Mtb was incubated with or without INH and CC-11050.
At 24, 48 and 72 h post-treatment, samples were serially diluted and
plated on 7H10 agar media. Colonies were enumerated after 3 weeks
of incubation at 37 °C.
2.6. Histology and Morphometry
Formalin-ﬁxed lung tissue sections from Mtb-infected rabbits were
stained with hematoxylin and eosin (H&E) to visualize cellular compo-
sition or with Ziehl–Neelsen acid fast staining (AFB) to visualize Mtb
(IDEXX-RADIL Laboratories Inc., MO). Masson's trichrome staining was
performed to examine collagen deposition and ﬁbrosis as previously de-
scribed (Subbian et al., 2012). Stained lung sections were analyzed and
photographed using a Nikon Microphot-FX photomicrographic system
with NIS-Elements F3.0 software (Nikon Instruments Inc., NY). Semiquantitative evaluation of pathologywas based on the following scoring
system: 0—intact lung; 1—increased cellularity; 2—granuloma forma-
tion; 3—granulomas with central necrosis; 4—large coalescent le-
sions with necrosis; 5—partial liquefaction; 6—extensive liquefaction;
7—cavity. Similarly, the extent of ﬁbrosis was scored using modiﬁed
Ashcroft scale: 0—normal lung (no ﬁbrosis); 1—minimal ﬁbrous thick-
ening of alveolar or bronchiolar vessels; 2—moderate thickening of
walls without obvious damage to lung architecture; 3—Increased ﬁbro-
sis with deﬁnite damage to lung structure and formation of ﬁbrous
bands or small ﬁbrous masses; 4—large ﬁbrous areas; 5—total ﬁbrous
obliteration of the ﬁeld (Hubner et al., 2008; Robbe et al., 2015). The
number and size of granulomatous lesions in the Mtb-infected rabbit
lung sections were enumerated by morphometric measurements
using Sigmascan Pro software (Systat Softwares, Inc., CA).2.7. Flow Cytometric Analysis
Single cell suspensions were prepared from rabbit spleen and
used for ﬂow cytometry as described previously (Subbian et al.,
2011c). Brieﬂy, spleenocytes were stained with CFSE (Life Technolo-
gies, Carlsbad, CA) and stimulated with concanavalin A (ConA) or
heat-killed Mtb or puriﬁed protein derivative (PPD) or left untreat-
ed. Cells were stained primarily with anti-rabbit CD4 or anti-rabbit
CD8 antibodies followed by APC anti-mouse IgG (BD Biosciences,
San Jose, CA). The samples were processed through FACSCalibur
ﬂow cytometer (BD Biosciences, San Jose, CA) and data was analyzed
using FlowJo software (Tree Star, Ashland, OR).2.8. RNA Isolation and Microarray Analysis
Total RNA from rabbit lungs was isolated using TRIzol reagent
(Invitrogen, CA) as described previously (Subbian et al., 2013a).
Portions of the lung tissue were homogenized with TRIzol, extracted
with chloroform and puriﬁed using NucleoSpin RNA II kit
(Macherey-Nagal, GmbH). The quality and quantity of puriﬁed RNA
was estimated using Nanodrop (NanoDrop Products, DE). One
microgram of total RNA from each rabbit lung was processed
separately for cDNA synthesis using a SuperScript II system (Agilent
Technologies, CA). cDNA from three rabbits per group was processed
independently for microarray experiments as described earlier
(Subbian et al., 2013a). The 4x44k rabbit microarray slide and
associated reagents were obtained from Agilent Technologies
(Agilent Technologies, CA). Synthesis of cDNA, labeling, hybridiza-
tion and post-hybridization washings were performed according to
the established, standardized protocols of the Center for Applied
Genomics (http://www.cag.icph.org/index.htm) of Rutgers University.
The slides were scanned and background-corrected probe intensity
was extracted using the Agilent Scanner and Feature Extraction Soft-
ware (Agilent Technologies, CA), respectively. Normalized data from
individual rabbits treated with CC-11050 or INH or INH + CC-11050
(n = 3 per group) were pooled respectively and compared to the
pooled data (n = 3) from the untreated but Mtb-infected control
group. One-way ANOVA followed by Bonferroni's test was performed
in Partek Genomics Suite, version 6.5 (Partek Inc., MO) and was used
to compare multiple experimental groups and treatment time. A false
discovery rate of less than 5% (FDR b 5%) was used as cut-off to identify
the statistically signiﬁcantly differentially expressed genes (SDEG) in
each of the treatment groups, relative to untreated controls. The list of
SDEG was loaded into QIAGEN's Ingenuity® Pathway Analysis (IPA®-
QIAGEN, CA) to determine signiﬁcantly enriched (P b 0.05; right-tailed
Fisher's Exact Test) biological functions, networks and canonical path-
ways as described previously (Subbian et al., 2013b). The microarray
data has been submitted to Gene Expression Omnibus (GEO), accession
number GSE74687.
Fig. 1. Experimental design and bacillary load in the lung, liver and spleen ofMtb-infected
rabbits. (a) Schema of experimental design showing rabbit infection, treatment and
necropsy time points. (b) Kinetics of bacillary growth in the lungs of Mtb-infected
rabbits with or without CC-11050, INH or INH + CC-11050 treatment. *P = 0.0223 at
12 weeks between untreated and INH-treated animals. **P = 0.006 at 12 weeks
between untreated and INH + CC-11050 treated animals. (c) Kinetics of bacillary
burden in the liver of Mtb-infected rabbits with or without CC-11050, INH or INH + CC-
11050 treatment. *P = 0.002 at 12 weeks between untreated and INH + CC-11050
treated animals. (d). Kinetics of bacillary load in the spleen of Mtb-infected rabbits with
or without CC-11050, INH or INH + CC-11050 treatment. Values plotted are mean and
standard deviation from 6 to 10 rabbits per group per time point.
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Total RNA from Mtb-infected rabbit lungs was reverse transcribed
using a Sprint RT system followingmanufacturer instructions (Clontech,
CA) and used in qPCR as described before (Subbian et al., 2011a).
Five nanograms of cDNA was mixed with gene-speciﬁc primer pair
and 2xSYBR green master mix; ROX dye was included as internal con-
trol and the reaction was set up as recommended by the manufacturer
(Takara, CA). Host GAPDH genewas used as internal control in all tested
samples. The qPCRwas performed in a StrategeneMx3005p instrument
and the datawas analyzed usingMxPro Software (Agilent Technologies,
CA) to determine threshold cycle (Ct). Change in gene expression was
calculated using the formula 2−ΔCt, whereΔCt is the difference in Ct be-
tween target gene and GAPDH. Nucleotide sequence of gene speciﬁc
primers used in this study is shown in Supplementary Table 1.
2.10. Statistical Analysis
Themicroarray datawas analyzed byANOVAusing Partek Genomics
Suite, version 6.5 (Partek Inc., MO) to select signiﬁcantly differentially
expressed genes (SDEG) as reported earlier (Subbian et al., 2013b). Stu-
dents' t-test from Microsoft Excel 2007 and GraphPad Prism software
(GraphPad Software, CA) was used to compare pair-wise signiﬁcance
for the bacterial CFU assay, pathologic analysis, T-cell proliferation
assay and qPCR experiments. For all experiments P b 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Pharmacokinetics of CC-11050
Peak plasma concentrations were reached between 4 and 8 h (Tmax)
following single or multiple 25 and 50 mg per kg doses of CC-11050
(Supplementary Fig. 1). There were no signiﬁcant differences observed
in the maximum concentrations (Cmax) reached at Tmax after one day or
4 days of oral dosing within the 25 mg per kg per day or 50 mg per kg
per day dose groups (Supplementary Table 2a). The mean exposures
calculated from the area under the concentration curve (AUC[0–24]) in-
creased proportionately to the dose on both day 1 and day 4. In addition,
about a two-fold increase in mean CC-11050 accumulation was ob-
served at both dose levels (Supplementary Table 2a). As shown in
Supplementary Table 2b and Supplementary Fig. 2, the plasma concen-
tration of INH was not affected by co-administration of CC-11050.
3.2. Adjunctive CC-11050 Treatment With INH Signiﬁcantly Reduces Tissue
Bacillary Loads
To determine the efﬁcacy of CC-11050 at improving the antimicro-
bial activity of the TB drug INH, we measured the number of CFU in the
lung, liver and spleen of aerosol infected rabbits at various time points
post-exposure or treatment (Fig. 1a). About 3.3 log10 CFU of Mtb
HN878 implanted in rabbit lungs on day 0 (3 h post-infection), prolif-
erated to about 7 log10 CFU after 4 weeks (Fig. 1b and Supplementary
Table 3). In the untreated rabbits the bacillary load remained high at
8 weeks (mean = 6.6 log10) and 12 weeks (mean = 6.2 log10) post-
infection. Treatment with CC-11050 alone for 4 weeks or 8 weeks
(8 weeks or 12 weeks post-infection) did not affect the number of
CFU signiﬁcantly compared to the untreated rabbits (P = 0.949 and
0.073, respectively), suggesting that CC-11050 does not have any in-
herent anti-mycobacterial activity. Treatment of Mtb-infected rabbits
with INH alone for 4 weeks moderately reduced the lung bacillary
load; however, after 8 weeks of treatment a signiﬁcant reduction
in the number of CFU was noted (P = 0.0223), compared to the un-
treated animals (Fig. 1b). There was no signiﬁcant difference in CFU
between CC-11050-treated and INH treated rabbits after 4 weeks
(P = 0.562) or 8 weeks (P = 0.39) of treatment (i.e., 8 and 12 weekspost infection).Treatment of Mtb-infected rabbits with INH + CC-
11050 for 4 weeks reduced the lung bacillary load but this effect was
not statistically signiﬁcant, compared to the other groups. However, a
signiﬁcant reduction in the lung bacillary load was observed after
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(P = 0.006) or INH alone treated (P = 0.0055) animals (Fig. 1b). At
these time points, signiﬁcant difference was noted between the CC-
11050-treated and CC-11050 + INH treated rabbits (P = 0.043 for
4 weeks and P = 0.006 for 8 weeks of treatment). This observation
suggests that immune modulation with CC-11050 can improve INH-
mediated killing of Mtb in the rabbit lungs. It is important to note
that when CC-11050 was used alone, the bacillary growth did not in-
crease, as seen when the host immune response is inhibited
(i.e., immune suppression). Tubercle bacilli were also recovered in sig-
niﬁcant numbers from the livers and spleens of all infected animals at
4 weeks post infection (Fig. 1c and 1d), suggesting bacillary dissemina-
tion from the lungs. A signiﬁcant reduction in the liver bacterial load
was noted only in rabbits treated with INH + CC-11050 for 8 weeks.
In the spleen, the lowest number of CFU was also observed in the
same treatment group.3.3. CC-11050 Treatment Did Not Affect the Bacterial Susceptibility to INH
To determinewhether CC-11050 affectMtb susceptibility to INH,we
performed CFU assay using lung homogenates of rabbits treated with
CC-11050 with or without INH. No signiﬁcant difference was observed
in the number of CFU obtained between INH and INH plus CC-treated
samples (data not shown). In addition, in vitro INH susceptibility testing
of Mtb with or without CC-11050 did not show signiﬁcant difference
between these two groups (Supplementary Fig. 3).Fig. 2.Gross pathology and disease characteristics ofMtb-infected rabbit lungs. (a–d)Represent
INH+ CC-11050- (d) treated rabbits showing the distribution of dorsal sub-pleural granuloma
images of rabbit lung sections at 12weeks post-infection, stainedwith hematoxylin & eosin, sho
INH (g) or INH+ CC-11050 (h) treated rabbits. Scale bar= 1mm. (i) Number of sub-pleural lu
rabbits at 12weeks post-infection. Values plotted are average and standard deviation from 6 to 8
(j) Area of lung granulomas inMtb-infected untreated, CC-11050-, INH- or INH+CC-11050 tre
from3 sections per animal; 6–8 animals per group. *P=0.013 between untreated and INH+CC
INH+CC-11050 treated rabbits at 12weeks post-infection. Values plotted are average and stan
11050 treated animals.3.4. CC-11050 Plus INH Treatment Dampens Disease Burden
To estimate the overall disease burden of Mtb-infected rabbits with
or without any treatment, net weight of the lung, liver and spleen was
measured after 4 or 8 weeks post-treatment (Supplementary Fig. 4).
No signiﬁcant difference in the weights of these organs was noted be-
tween the untreated rabbits and those treated with CC-11050 or INH
with or without CC-11050.
To evaluate the development of granulomas over time, whole rabbit
lungs fromall groups of theMtb-infected (treated or untreated) animals
were examined for gross pathology at the end of treatment (12 weeks
post-infection) (Fig. 2a and h). The lesions in the untreated (Fig. 2a
and e) and CC-11050-alone treated (Fig. 2b and f) rabbits appeared
larger than those noted in the other treatment groups. Although INH
alone-treated animals had smaller visible lesions at 4 or 8 weeks of
treatment (Fig. 2c and g), the smallest lesions were observed in the
lungs of rabbits treated with INH + CC-11050 at these times (Fig. 2d
and h). In the combination therapy group,most of the lung parenchyma
appeared normal and unlike the other groups, a number of the lung sec-
tions had no lesions at all.
The total number of sub-pleural lesions counted in both lungs of un-
treated Mtb-infected rabbits was about 80 at 4 weeks post-infection.
This number did not change signiﬁcantly at 12 weeks post-infection
in the untreated, the CC-11050 alone- or INH alone-treated animals
(Fig. 2i). In contrast, rabbits treated for 8 weeks with INH + CC-11050
had a signiﬁcantly lower number of visible sub pleural lesions, com-
pared to the other groups (P b 0.0001) (Fig. 2i).ative gross lung pathology images ofMtb-infecteduntreated (a), CC-11050- (b), INH- (c) or
s at 12weeks post-infection (8 weeks treatment). (e–h) Representative lowmagniﬁcation
wing the general architecture of granulomas inMtb-infected untreated (e), CC-11050- (f),
ng granulomas inMtb-infected untreated or CC-11050 or INH or INH+ CC-11050 treated
animals per group. *P=0.0003 between untreated and INH+CC-11050 treated animals.
ated rabbits at 12 weeks post-infection. Values plotted are average and standard deviation
-11050 treated animals. (k) Pathology score ofMtb-infecteduntreated, CC-11050-, INH- or
dard deviation from 6 to 8 animals per group. *P=0.04 between untreated and INH+CC-
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revealed signiﬁcant differences in the size of the lesions (Fig. 2j). In
the untreated animals, the granulomas at 12 weeks post-infection
reached about 1 mm2. No signiﬁcant difference in the lesion area was
noted between the untreated and CC-11050- or INH-alone treated
animals, although the latter group had moderately reduced lesion size.
Importantly, the greatest reduction in granuloma size was noted in
the lungs of INH + CC-11050 treated rabbits (average = 0.102 mm2)
which was signiﬁcantly lower compared to the untreated (P = 0.013)
or INH-alone treated (P = 0.040) animals at 12 weeks post-infection
(Fig. 2j).
To determine the extent of disease manifestations in the lungs, we
scored the pulmonary pathology at the end of treatment (Fig. 2k). The
untreated and INH-alone treated group had the highest disease compli-
cations, followed by the CC-11050 treated rabbits that showed amoder-
ately reduced disease at 12 weeks post infection. In contrast, signiﬁcant
reduction (P = 0.04) in disease pathology was observed at this timeFig. 3.Histopathology ofMtb-infected rabbit lungs 12weeks post infection (8weeks of treatmen
untreated rabbits.Well demarcated, large conﬂuent granulomaswith central necrosis andmine
of acid-fast bacilli (arrowheads) were also found in these granulomas. (d, e and f) Representat
11050 only. Well demarcated, large lesions with central necrosis surrounded by multiple ep
noted in these granulomas. (g, h and i) Representative images of H&E (g and h) or AFB (i) st
extensive necrosis and mineralization, surrounded by foamy macrophages and lymphocytes
l) Representative images of H&E (j and k) or AFB (l) stained lung section from rabbits treate
small granulomas, undergoing resorption can be seen. No clearly visible AFB-positive organi
(Scale bar = 500 μm) and b, e, h and k at 40× (Scale bar = 50 μm) magniﬁcation, respective
magniﬁcations.in the INH + CC-11050 treated, compared to the untreated rabbits
(Fig. 2k).
3.5. CC-11050 Plus INH Treatment Alleviates Lung Necrosis and Tissue
Damage
Detailed, higher magniﬁcation histologic examination of the Mtb-
infected rabbit lungs at 4 weeks showedmultiple, well organized gran-
ulomas (size 0.5–1.5 mm diameter), some of which had initial central
necrosis (not shown). At 12 weeks, untreated rabbits hadmultiple coa-
lescent lesions with extensive necrosis, surrounded by macrophages
andmany lymphocytes (Fig. 3a and b). In somegranulomas,mineraliza-
tion (calciﬁcation) was seen. Polymorphonuclear leukocytes (PMNs)
were observed at the border of the necrotic areas. Animals treated
with CC-11050 alone, at 12 weeks post-infection (8 weeks of treat-
ment), had similar large necrotic lesions (Fig. 3d and e), containingmul-
tiple epithelioid macrophages and less lymphocytes. INH-treatedt). (a, b and c) Representative images of H&E (a and b) or AFB (c) stained lung section from
ralization, surrounded bymacrophages andmany lymphocytes can be seen. High numbers
ive images of H&E (d and e) or AFB (f) stained lung section from rabbits treated with CC-
ithelioid macrophages and less lymphocytes can be seen. Very few acid-fast bacilli are
ained lung section from rabbits treated with INH only. Granulomas with central area of
can be seen. Very few AFB-positive organisms were found in these granulomas. (j, k and
d with the combination of INH and CC-11050. Very few, well demarcated, non-necrotic
sms were observed in these granulomas. Figures a, d, g and j were photographed at 4×
ly. Sections c, f, i and l (acid-fast stain) were photographed at 80× (Scale bar = 25 μm)
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the untreated animals. The granulomas contained central area of
necrosis and mineralization, surrounded by foamy macrophages and
lymphocytes in the periphery (Fig. 3g and h). In contrast, signiﬁcantly
fewer and smaller granulomas (b0.5 mm diameter) were present in
the INH + CC-11050 treated rabbits relative to the controls and other
treatment groups (Fig. 3j and k). Most of the lesionswere in the process
of undergoing resorption and had no central necrosis. These observa-
tions were conﬁrmed by a semi quantitative evaluation of lung pathol-
ogy (see Section 2). The average disease score for animals treated
with INH + CC-11050 was signiﬁcantly lower than the control group
and rabbits treated with INH alone (1.7 vs. 5 and 4.3 respectively;
P = 0.0006 and 0.003 respectively). Acid-fast staining revealed nu-
merous bacilli, mostly intracellular in the lesions from the control un-
treated rabbits (Fig. 3c). Few single AFB were found in the necrotic
zone of the granulomas of INH- or CC-11050-alone treated animals
(Fig. 3f and i) and none in the lesions of INH+CC-11050 treated rabbits
(Fig. 3l).
3.6. Effect of CC-11050 Treatment on Immune Cell Function
Todetermine the extent of T cell activation, spleenocytes isolated from
Mtb-infected rabbits that were untreated or drug treated, at 12 weeks
post-infection, were stimulated with PPD, ConA or heat-killed Mtb, and
their proliferative capacity was analyzed by CFSE dilution method using
a ﬂow cytometer as described previously (Subbian et al., 2011c). As
shown in Fig. 4, in the absence of any antigen stimulation, the percent
of proliferating CD4+ T cells was signiﬁcantly reduced in the CC-11050
(P= 0.033) or INH (P=0.002) or INH+CC-11050 (P = 0.008) treated,
compared to the untreated animals. Similar reductions in proliferating
CD4+ T cells were also noted between the untreated and treated ani-
mals, upon stimulation with heat-killed Mtb (P = 0.017 for CC-11050;
P=0.022 for INH; P=0.008 for INH+CC-11050). In contrast to the pro-
liferating CD4+ T cells, no signiﬁcant difference was observed in the per-
cent of proliferating CD8+ T cells between the untreated and different
treatment groups (Supplementary Fig. 5) exposed ex vivo to the different
antigens.
3.7. Global Lung Transcriptome of Mtb-infected Rabbits With or Without
CC-11050 Treatment
To understand the effect of CC-11050 treatment on the host response
in the lungs of Mtb-infected rabbits, we performed microarray-based
global gene expression proﬁling analysis. Compared to the uninfected an-
imals, 11,701 genes were signiﬁcantly differentially expressed (SDEG;
P b 0.05) in the Mtb-infected but untreated rabbit lungs at 12 weeksFig. 4. Proliferative capacity of CD4+ T cells. Percent of proliferating CD4+ T cells in Mtb-
infected untreated or CC-11050 or INH or INH + CC-11050 treated rabbits at 12 weeks
post-infection (8 weeks treatment). Rabbit spleenocytes were either un-stimulated or
stimulated with PPD, ConA or heat-killed Mtb before proliferation was measured by
FACS analysis. Values plotted are average and standard deviation from 6 to 8 animals
per group. *P b 0.05 compared to the untreated.post-infection (Supplementary Fig. 6a). At this time, expression of 8701
genes was signiﬁcantly affected in CC-11050 treated rabbit lungs, com-
pared to the untreated animals. In addition, 4433 SDEG were commonly
affected between the untreated and CC-11050 treated rabbit lungs.
Among these common SDEG, expression of 1108 geneswas up-regulated
and 3325 were down-regulated in the untreated rabbit lungs, compared
to 1114 up-regulated and 3319 down-regulated genes in CC-11050 treat-
ed animals (Supplementary Fig. 6b). The quality of microarray gene ex-
pression was validated by qPCR ampliﬁcation of randomly selected host
immune genes. As shown in Supplementary Table 4, the direction of ex-
pression of all tested genes as well as the level of expression of several
genes were consistent between microarray and qPCR.
3.8. Gene Ontology Analysis of SDEG
To understand the biological functions, cell signaling networks and
pathways that are affected by CC-11050 treatment, we performed gene
ontology analysis on the SDEG from Mtb-infected untreated or CC-
11050 treated rabbits, compared to the uninfected controls (Fig. 5). In
the untreated rabbit lungs, genes associated with biological functions in-
cluding inﬂammation, respiratory disease, lipidmetabolism, cell compro-
mise, infectious disease, immunological disease, smallmolecule transport,
cell death andorganismal injurywerehighly signiﬁcantly enrichedduring
Mtb infection. However, the signiﬁcance of enrichment for most of these
disease-associated functions, networks and pathways was less pro-
nounced in the CC-11050 treated animals. Importantly, no signiﬁcant en-
richment of inﬂammatory response associated geneswas noted in the CC-
11050 treated rabbit lungs. Consistently, genes encoding for inﬂammato-
ry molecules, including GZMA, GZMB, FAM26F, MMP1, CXCL9, CXCL13,
SLAMF7 were very highly up-regulated (N25 fold) and were among the
top 10 most induced in the Mtb-infected untreated rabbit lungs (Supple-
mentary Table 5). In contrast, except for GZMA, other genes were not sig-
niﬁcantly differentially expressed in the CC-11050 treated animals,
compared to the uninfected animals.
3.9. CC-11050 Treatment Dampens Macrophage Activation and
Inﬂammatory Response
To further elucidate the effect of CC-11050 treatment speciﬁcally on
the host inﬂammatory response, we analyzed the expression proﬁle
of genes associated with the following networks: a) TNF-α regulation,
b) macrophage activation and c) lung inﬂammation (Supplementary
Fig. 7).
3.9.1. TNF-α Regulon Network
Among the SDEG, a subset of 205 genes in Mtb-infected rabbit lungs
was associated with the regulation of TNF-α (Supplementary Fig. 7a
and Supplementary Table 6). Of these, expression of 122 genes was up-
regulated, including 31 genes expressed greater than 5-fold, and 83
were down-regulated in the untreated animals. In contrast, 50 genes
were up-regulated, 47 genes were down-regulated and 108 genes
were not signiﬁcantly expressed in the CC-11050 treated rabbit lungs.
In these animals, only 4 out of 50 genes were expressed to greater
than 5-fold. Interestingly, 44 out of 50 up-regulated genes and 46 out
of 47 down-regulated genes in CC-11050 treated rabbitswere expressed
in the same direction as the untreated, though the level of expression
was lower in the CC-11050 treated group. Expression of MCL1, CCL2,
SMPDL3A and LOX was down-regulated and THY1 was up-regulated in
the CC-11050 treated animals; these genes were expressed in the oppo-
site direction in the untreated rabbit lungs (Supplementary Table 5).
3.9.2. Macrophage Activation Network
There were 68 genes associated with macrophage activation in Mtb-
infected rabbit lungs at 12 weeks post-infection (Supplementary Fig. 7b
and Supplementary Table 6). Among these, expression of 55 genes was
up-regulated, including 15 genes induced to at least 5 fold. The number
Fig. 5. Gene ontology analysis of signiﬁcantly differentially expressed genes (SDEG) in Mtb-infected rabbit lungs. SDEG were selected based on 5% FDR and analyzed using Ingenuity
Pathway Analysis (IPA) to determine enriched biological functions in the lungs of Mtb-infected untreated or CC-11050 treated rabbits at 12 weeks post-infection. Biological functions
with a P b 10−3 were considered signiﬁcant. Inﬂammatory response network and pathways were not signiﬁcantly enriched in the CC-11050 dataset.
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only 3 genes expressed to greater than 5 fold in the CC-11050 treated rab-
bit lungs. Expression of 20 out of 23 genes was in the same direction (up-
regulated);while expression of LCP1,CCL2 and STAT3was regulated in the
opposite direction, between the untreated and CC-11050 treated rabbits
(Supplementary Table 5). Though similar number of genes was down-
regulated in the untreated (13 genes) and CC-11050 treated (12 genes)
animals, expression of 23 genes was noted only in the former group.
3.9.3. Lung Inﬂammation Network
Of the 103 genes associated with lung inﬂammation, 65 genes were
up-regulated and 38 genes were down-regulated in the untreated rab-
bit lungs (Supplementary Fig. 7c and Supplementary Table 6). AmongFig. 6. Lung ﬁbrosis inMtb-infected rabbits with or without CC-11050 treatment at 12 weeks p
rabbits. Signiﬁcant collagen deposition (blue staining) can be seen around the granulomas. (b an
collagen deposition (blue staining) surrounding thenecrotic lesions can be seen in f. (c and g)Re
less staining was observed in these granulomas. (d and h) Representative image of lung section
surrounding the granuloma in h. All sections were stained using Masson's trichromemethod. I
(Scale bar = 50 μm), respectively.the up-regulated genes, a subset of 22 genes was also up-regulated in
CC-11050 treated animals. Similarly, 20 down-regulated genes in this
group were also down-regulated in the untreated rabbits.
Twenty one SDEG were shared between the TNF-a regulon, macro-
phage activation and lung inﬂammation networks (Supplementary
Fig. 8a and Supplementary Table 6). Of these, 18 geneswere up-regulated
and 3 genes were down-regulated in the untreated animals, compared
to 6 up-regulated genes and 4 down-regulated genes in CC-11050
treated animals. Notably, expression of TNF, CD14, IFNGR2, CD4, IL12B,
IL16 and CCL2 was highly up-regulated only in the untreated rabbits
(Supplementary Fig. 8b and Supplementary Table 5). As shown in Sup-
plementary Fig. 7, the expression of genes associated with TNF-α
regulon, lung inﬂammation, macrophage activation and lung ﬁbrosisost infection. (a and e) Representative image of lung sections fromMtb infected untreated
d f) Representative image of lung sections from rabbits treatedwith INH alone. Signiﬁcant
presentative image of lung sections from rabbits treatedwith CC-11050 alone. Signiﬁcantly
s from rabbits treatedwith INH+ CC-11050. Minimal amount of ﬁbrosis can be visualized
mages a–d were photographed at 4× (Scale bar = 500 μm) and e–h at 40× magniﬁcation
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(Supplementary Fig. 9).
3.10. CC-11050 Treatment Affects Lung Fibrosis
To evaluate the effect of CC-11050 on the extent of the ﬁbrotic pro-
cess, lung sections from all treated and untreated infected rabbits were
stained using Masson's trichrome method, speciﬁc for ﬁbrosis, collagen
deposition and tissue remodeling (Fig. 6). Microscopic examination re-
vealed little to noﬁbrosis in the lungs at 4 or 8weeks post-infection (not
shown). At 12 weeks post-infection, signiﬁcant collagen deposition
(blue staining) was observed around the granulomas and adjacent
to the necrotic area in the lungs of control untreated Mtb-infected ani-
mals (Fig. 6a and e). Based on the Ashcroft scoring system the average
value was 2.8. Similarly, extensive ﬁbrosis was seen in the lungs of
animals treated with INH alone (Fig. 6b and f) (Ashcroft score — 2.7).
In contrast, the lungs of animals treated with CC-11050 alone (Fig. 6c
and g) contained granulomas with almost no ﬁbrosis (Aschroft score
— 0.8) and INH + CC-11050 treated rabbit lungs (Fig. 6d and h) had
very minimal amounts of ﬁbrosis, with an average score of 0.5. These
ﬁndings demonstrate that eight weeks of treatment with the CC-
11050 or the combination of CC-11050 and INH resulted in diminished
infection-induced ﬁbrosis around and within lung lesions.
3.11. Modulation of Lung Fibrosis and Wound Healing Network by
CC-11050 Treatment
Since histologic staining showed diminished ﬁbrosis in CC-11050
treated, compared to the untreated rabbit lungs, we investigated the
transcriptional proﬁle of lung ﬁbrosis and wound healing network
genes at 12 weeks post-infection. Of the SDEG, a subset of 59 genes
was associated with the lung ﬁbrosis network (Fig. 7a and Supplemen-
tary Table 6).While expression of 36 genes (61%)was up-regulated andFig. 7. Expression proﬁle of lung ﬁbrosis network genes in Mtb-infected rabbits with or withou
Mtb-infected untreated (UT) or CC-11050 treated (CC) rabbit lungs at 12 weeks post-infection
intensity of color denotes relative level of respective gene expression. The scale bar ranges from
shown in Supplementary Table 5. (b) qPCR analysis of selected genes involved in ﬁbrosis and
rabbits at 12 weeks post-infection. *P b 0.05 compared to the untreated.23 geneswere down-regulated in theuntreated, only 11 geneswere up-
regulated and 7 genes were down-regulated in the CC-11050 treated
rabbit lungs. In the later group of animals, 41 genes (69%) were not sig-
niﬁcantly expressed. To further elucidate the expression pattern of
genes involved in tissue remodeling, we performed qPCR on selected
host genes that code for collagenase (MMP1), gelatinase (MMP2), elas-
tase (MMP12) and membrane-type (MMP14) matrix metalloproteases
and a matrix proteoglycan, decorin (DCN) (Fig. 7b). Compared to the
Mtb-infected untreated animals, expression ofMMP1, MMP12,MMP14
and DCN was signiﬁcantly reduced (P b 0.05) in the CC-11050 treated
rabbit lungs at 12weeks post-infection (8weeks of treatment). In addi-
tion,MMP12 was signiﬁcantly reduced in the INH + CC-11050 treated
group, compared to the untreated rabbits. No signiﬁcant difference
was observed between INH treated versus untreated rabbit lungs for
any of the tested genes. Taken together, our qPCR results are consistent
with and support the histologic ﬁnding of reduced ﬁbrosis in CC-11050
treated rabbit lungs.4. Discussion
Host-directed therapy is being actively pursued as an alternate strat-
egy to cure TB.
In this study, we found that coupling INH therapy with adjunctive
PDE4i CC-11050 treatment signiﬁcantly reduced the bacillary burden
and tissue inﬂammation and improved lung pathology in Mtb-infected
rabbits. Consistently, lung ﬁbrosis was signiﬁcantly reduced in the
CC-11050 treated animals. Lung transcriptome analyses revealed damp-
ening of the expression of genes associated with TNF-α, macrophage
activation and lung inﬂammation networks. Our results strongly sug-
gest that CC-11050 can be used as an adjunct therapeutic molecule to
improve the outcome of antibiotic treatment in patients with pulmo-
nary TB.t CC-11050 treatment. (a) Intensity plot of SDEG associated with lung ﬁbrosis network in
. Red color indicates up-regulated genes; blue color represents down-regulated genes and
+3 (red) to−3(blue). Individual genes in this network and their expression levels are
tissue remodeling in the lungs of Mtb-infected untreated (UT) or CC-11050 treated (CC)
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dampening the host inﬂammatory response by down-regulating TNF-
α through PDE4 inhibition therapy can improve the outcome of antibi-
otic treatment during Mtb infection. In contrast, in a recent mouse
model of Mtb infection, treatment with rolipram and cilomilast, two
FDA approved PDE4i used for the treatment of depression and COPD re-
spectively, in combination with anti-TB drugs did not show signiﬁcant
improvement in disease or reducing the bacillary load (Maiga et al.,
2013). This difference between the published study and our work
might reﬂect the different enzyme speciﬁcities of these three PDE4i.
The PDE4 family has at least 4 subtypes (PDE4A-4D) and at least 15
isotypes that are differentially localized and expressed among the host
immune cells (Houslay & Adams, 2003). In vitro, rolipram inhibits
PDE4A, 4B and 4D activities, with higher and similar inhibitory activity
towards PDE4B and 4D (MacKenzie & Houslay, 2000). It is likely that
the speciﬁc PDE4 isoforms targeted by CC-11050 differ from those
targeted by rolipram. In addition, unlike the rabbit, the standard
mouse model of pulmonary Mtb infection does not recapitulate the
pathologic sequence of TB manifestations found in humans, such as ne-
crosis, hypoxic lesions and cavitation (Gupta & Katoch, 2005; O'Toole,
2010). Since the effect of immune modulators on TB pathology and as-
sociated host gene expression varies signiﬁcantly between murine and
rabbit models, the results obtained in the twomodels cannot be directly
comparable In addition, the divergent results between the current study
and a report by Maiga et al. (2013) may be due to the difference in the
treatment regimen (single-versus multi-drug combinatorial therapy).
A critical observation in this study is the reduced lung ﬁbrosis during
CC-11050 treatment ofMtb-infected rabbits. One of the hallmarks of ad-
vanced pulmonary TB in humans is the extensive tissue damage due to
cavities that are surrounded by thick ﬁbrosis (Kaplan et al., 2003;
Subbian et al., 2015). Although tissue remodeling during ﬁbrosis aids
in the stabilization and healing of granulomas with caseation, extensive
ﬁbrosis resulting in tissue scarring, signiﬁcantly reduces lung function
(Hunter, 2011a; Hunter, 2011b). In addition, granulomas with ﬁbrosis
and extensive tissue remodeling have poor drug penetration and
accumulation resulting in poor bactericidal activity by the anti-TB
drugs (Kjellsson et al., 2012). Moreover, Mtb can thrive in a ﬁbrotic
lesion and can be reactivated during immune suppression (Paige &
Bishai, 2010).
Matrix metalloproteases (MMPs) are a family of cellular matrix
degrading nucleases that play a central role in tissue remodeling and ﬁ-
brosis during pulmonary cavitary TB in humans and in relevant animal
models; small molecules that can interfere with MMP signaling have
been suggested as immunomodulatory drugs for TB treatment (Ong
et al., 2014; Elkington et al., 2011; Dharmadhikari & Nardell, 2008). In
general, induction of several MMPs, including MMP1, MMP12 and
MMP14 correlates with disease severity, tissue destruction and inﬂam-
mation during active TB in humans and in the non-human primates
and rabbit models of pulmonary TB (Subbian et al., 2011b; Subbian
et al., 2015; Ong et al., 2014; Kim et al., 2010;Mehra et al., 2010). Consis-
tentwith these ﬁndings, we observed up-regulation ofMMP1, 12, 14 and
DCN inMtb-infected untreated rabbit lungs associatedwith increased ﬁ-
brosis around the granulomas.We postulate that in the CC-11050+ INH
treated rabbits, signiﬁcant down-regulation of theseMMPs, concomitant
with a dampened inﬂammatory response, contributes to reduced ﬁbro-
sis, and that this facilitates improved accessibility of antibiotics and im-
proved bacterial killing. We believe that these ﬁndings can provide a
rationale for developing CC-11050 as an adjunctive agent in TB therapy.
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